Akari Therapeutics PLC (AKTX) Stock Price Up -8.9%
Akari Therapeutics PLC (NASDAQ:AKTX) shares rose 8.9% during trading on Thursday . The stock traded as high as $8.65 and last traded at $6.74. Approximately 229,444 shares traded hands during trading, a decline of 38% from the average daily volume of 367,823 shares. The stock had previously closed at $7.40.
AKTX has been the subject of several research reports. Canaccord Genuity reissued a “buy” rating and set a $15.00 price objective (down previously from $33.00) on shares of Akari Therapeutics PLC in a report on Monday, June 26th. Zacks Investment Research downgraded shares of Akari Therapeutics PLC from a “strong-buy” rating to a “hold” rating in a report on Monday, September 18th. William Blair reissued an “outperform” rating on shares of Akari Therapeutics PLC in a report on Tuesday, July 4th. Chardan Capital reissued a “neutral” rating and set a $2.50 price objective (down previously from $6.00) on shares of Akari Therapeutics PLC in a report on Friday, August 11th. Finally, ValuEngine raised shares of Akari Therapeutics PLC from a “strong sell” rating to a “sell” rating in a report on Monday, September 11th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $8.00.
The firm’s market cap is $80.55 million. The stock’s 50 day moving average is $5.40 and its 200 day moving average is $7.23.
An institutional investor recently bought a new position in Akari Therapeutics PLC stock. Hikari Power Ltd purchased a new position in shares of Akari Therapeutics PLC (NASDAQ:AKTX) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 60,012 shares of the biopharmaceutical company’s stock, valued at approximately $277,000. Hikari Power Ltd owned about 0.51% of Akari Therapeutics PLC at the end of the most recent quarter. 26.85% of the stock is owned by hedge funds and other institutional investors.
Akari Therapeutics PLC Company Profile
Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.
Receive News & Ratings for Akari Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.